Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
SAN DIEGO, April 05, 2016 -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA: David Schull Russo Partners, LLC (858) 717-2310 [email protected] INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
